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Private-sector caesarean sections in perspective 
Alan D Rothberg, Heather McLeod 
In a recent issue of the Journal,' views were expressed that our 
national private sector caesarean section (CS) rate is too high at 
over 60%, and government and/or funders are likely to 
intervene unless doctors begin to self-regulate by developing 
appropriate protocols and guidelines. This is not a new issue 
for South Africa or for medically insured populations around 
the world, and the sheer volume of literature on the subject of 
high CS rates indicates that it is unlikely one will reach 
consensus on a national target CS rate simply by means of a 
decree, whether issued by providers or regulators. 
However, what is not clear from Chris Bateman's article' is 
whether the core issue is one of women's (and children's) 
health, of consumption of scarce financial resources, of concern 
about doctors being exposed to medico-legal risk, or of a 
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patient's right to choose a health intervention that may not be 
medically necessary. 
Is the concern around health or costs? 
We contend that this is not primarily about maternal and child 
health or about exposure to unnecessary anaesthetic and 
operative risk, because if the country was truly concerned 
about such matters we would have acted long ago to reduce 
rates of cosmetic surgery. In general we accept a patient's right 
to undergo procedures such as breast reduction, augmentation 
and liposuction, but deal with them on the basis of the 
patient's willingness to self-fund, assuming of course that 
consent for surgery has always been fully informed and all 
risks have been explained. Bateman's article implies that in the lll'.:"r.:JJ 
case of CS the risks are not fully explained and that women ~ 
might be unreasonably and unnecessarily influenced by their 
doctor's bias. 1 Overseas research does not consistently support 
this contention; in fact several recent studies'·' show that the 
overwhelming majority of obstetricians favour vaginal 
delivery. However the data further indicate that most 
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obstetricians also respect their patients' right to choose how 
their babies will be delivered.4•5 
As already stated, South Africa respects patient choice in the 
context of medically unnecessary cosmetic procedures and we 
can probably also invoke patient choice in other areas where 
rates may be higher than necessary. For example, research 
abounds to demonstrate that large numbers of circumcisions, 
tympanostomy tube placements and wisdom teeth removals 
are not medically necessary. Certainly some have definite 
medical indications, but one should probably conclude that the 
others are performed as a result of patient or parental choice 
following informed consent (although in some of these 
examples the doctor's or dentist's bias will almost certainly 
influence the nature of the information and how a patient or 
parent will respond). 
The medico-legal issue is a real one, but in truth the debate 
does not revolve around concern for the doctor. Certainly 
there is a chance of an obstetrician being sued for performing a 
CS that was not medically necessary, and informed consent and 
patient choice would no doubt be central evidentiary themes in 
any legal proceedings, but in practice, doctors are far more 
likely to be sued for not performing a CS, usually following 
delivery of a damaged infant. This aspect has prompted many 
to conclude that high CS rates are the result of obstetricians 
practising 'defensive medicine,' but even that contention has 
been negated by research.6•7 
What is the CS rate supposed to be and 
what can be done to influence it? 
Logic dictates that nature cannot have devised a birth process 
that most often relies on unnatural surgical intervention to 
bring it to its natural conclusion, so based on first principles a 
rate in excess of 60% must be too high- but what is the 
appropriate rate? 
There is already agreement around standard maternal and 
fetal indications for either elective or emergency CS, viz. fetal 
distress, cephalopelvic disproportion, placenta praevia, 
eclampsia, breech presentation, etc. Particularly relevant to 
South Africa is the importance of CS in the prevention of 
mother-to-child transmission of HIV8 and this would obviously 
increase the base rate of the procedure. Taking all factors into 
account, the Bateman article cites current CS rates for private 
and public sectors of 65% and 25% respectively, and implies 
that even our public-sector rates are high. 1 We submit that our 
public-sector rates might actually be lower than appropriate, 
not only because of the HIV pandemic and high rates of 
infection in antenatal clinic attendees, but also because fairly 
common public-sector resource issues (e.g. access to care and 
staff, theatre, equipment and linen shortages) might result in 
vaginal delivery of cases that would more appropriately be 
delivered operatively. In the end we are still left with a sense 
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that 65% is definitely too high, but getting to the 'right' number 
is not easy. 
Over the years funders both locally and internationally have 
devised strategies to force CS rates down, mostly without 
success. An extremely aggressive approach was cited by 
Bateman, i.e. that of a UK health care fund that has apparently 
taken the decision to deny payment for all CSs because of the 
excess of cases that were not medically necessary.1 At the other 
extreme, reference is made to a dominant local £under with a 
generous policy of universal cover for CS, whether medically 
necessary or not. 1 Other local experiences over the years 
include higher professional fees for vaginal delivery than for 
CS, and even cash rebates for women who elected to deliver at 
home. In terms of the latter examples, one can clearly picture 
the awkward position of a funder or obstetrician if challenged 
in court to defend such perverse incentives in the event of 
problems that resulted in fetal death or damage. Other 
strategies such as routine second opinion before approval for 
CS have also not been successful.' 
An issue that will require specific attention in the medical 
schemes environment is that of CS rates in the emerging 
market, i.e. within low-cost schemes or options that are being 
developed for lower-income groups, typically those that have 
previously not been covered. The health care delivery model 
for this population usually focuses on clinic-based primary 
health care, with a nurse acting as 'gatekeeper'. Recent 
research within the Medscheme environment strongly suggests 
that where the model specifies antenatal care at the primary 
health care clinic but permits delivery at a private hospital 
(because the clinics typically do not provide maternity 
services), then delivery tends to be by a specialist and the CS 
rate is still fairly high at 46% (versus the 57% CS rate in higher-
cost schemes or options).10 Low-cost medical scheme options 
or plans that offer antenatal care at clinics but restrict delivery 
to public-sector hospitals may well have lower CS rates, but 
here too the problem remains one of fragmented care. The 
Medscheme research also suggests that medical aid models 
that promote GP networks as the primary care providers have 
CS rates that are± 10% lower than for a population with 
immediate access to specialists.10 The implication here is that 
since GP networks are likely to become more prevalent in the 
future, the required service level agreements will most likely 
specifically target CS rates for reduction. 
An innovative proposal from the BHF 
Another model, one that currently enjoys favour with the 
Board of Healthcare Funders (BHF), would see delivery by a 
midwife as the prescribed minimum benefit (PMB) for normal 
pregnancy and birth. 11 The BHF subcommittee working on this 
has already recommended such an approach to the Council for 
Medical Schemes, its view being that midwife care in 
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pregnancy, birth and after birth offers many advantages 
including lower rates of CS. It is further recommended by BHF 
that, in addition to the midwife fees, schemes should cover two 
visits to an obstetrician during the pregnancy, and obviously 
cover the costs of specialist delivery where the midwife refers 
the patient. Patients would continue to have the freedom to 
choose their level of care, but the minimum benefit 
reimbursement for normal pregnancy and birth would be at 
the midwife level. The important principles to be noted here 
are the freedom lo choose the level of care, and the patient 
being responsible for payment for care above that level unless 
referred by the midwife for care and/ or delivery by a 
specialist. 
While fully appreciating the rationale, we nevertheless doubt 
that the BHF model would succeed if implemented 
immediately. Firstly, as already stated by the BHF, in order to 
attract midwives into the business of private-sector deliveries 
one would have to pay them substantially more than their 
current fees. This would reduce the differential between 
midwife and doctor costs, and in turn reduce or eliminate the 
financial incentive for a patient to seek care from a midwife. 
More important, however, is the problem of applying data 
from midwife-based practices to the broader medical scheme 
population. Midwives currently practise in communities that 
are demographically different from the broader covered 
population (and that are less disposed towards CS) or, where 
the demographics appear to be similar, midwives serve a sub-
group of women who differ attitudinally in terms of favouring 
natural childbirth, home delivery, etc., and it would be 
unrealistic to assume that a decree specifying midwife delivery 
as the PMB would override the demographic and attitudinal 
differences. 
In its recommendations to the Council for Medical Schemes, 
the BHF also makes reference to data implying that if elective 
CS rates are cut then certain cases of prematurity would also 
disappear; however, is it not more likely that an alternative to 
elective CS would simply be a planned induction of labour? 
Yes, CS has been shown to be associated with anaesthetic risks, 
higher maternal mortality, future pregnancy risks (e.g. 
stillbirth, rupture of a scarred uterus), but planned induction 
may also be associated with preterm delivery and also have 
significant maternal consequences.12-15 
Considering the arguments thus far one must reach the 
conclusion that the imperative is less about how to reduce the 
high CS rate and more about how the private sector should be 
authorising and/ or paying for the medically unnecessary CSs 
that are done predominantly as a result of patient choice. 
Clearly the profession should have specific guidelines that 
define the circumstances under which elective and emergency 
CS should be performed, but in general, such guidelines are 
non-contentious, have existed for years and (given appropriate 
resources) are almost certainly already being followed by 
practitioners. Undoubtedly there is still debate about how to 
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deliver a woman who has had a previous CS, and while 
research fairly universally shows that a trial of labour is 
appropriate and that almost all who undergo trials will deliver 
vaginally,14•15 in South Africa this subgroup continues to have a 
high CS rate. The latter is most likely again heavily influenced 
by the patient, who mostly has had a positive previous 
experience, but provider bias is probably also a factor because 
while failed trial of labour is uncommon, the maternal and fetal 
consequences of such failure are often disastrous.14•15 As for 
guidelines for the CS that is not medically necessary, one can 
only say that this is a contradiction in terms; however the 
patient should always be fully informed as to the risks to 
herself and her baby. 
Risk-sharing and the role of the Risk 
Equalisation Fund 
Turning now to the shifting of the burden of payment from the 
funders to the patient in the case of CS performed for non-
medical reasons, the BHF midwife model would do so by 
prescribing a delivery system with an inherently low CS rate, 
and establishing the midwife as the gatekeeper who would 
determine when a higher level of care should be fully funded. 
However, because of doubt that this model will universally 
find favour with women and/ or their doctors, perhaps as a 
first step the proposal should be piloted by those medical 
schemes serving lower-income groups, typically through 
network-based 'gatekept' models. Meanwhile one should also 
look to the other stakeholders (patients, doctors, funders) to 
fulfil the role of gatekeeper. As confirmed by Discovery Health 
in Chris Bateman's article/ doctors tend not to be the ideal 
gatekeepers because when challenged they will almost 
invariably supply some medical reason for a CS that was 
performed. It is also probably safe to say that provider 
behaviour is unlikely to change without incentives (e.g. built 
into network contracts) or financial or professional penalties 
being applied by the funders or the regulators for 'errant' 
behaviour.16 The focus must therefore shift to the medical 
scheme members and/ or the funders themselves. The former 
would probably respond fairly appropriately if scheme benefits 
were unequivocal, and member communications warned that 
in the event of a medically unnecessary CS they would be 
responsible for the difference between total costs of a vaginal 
versus an operative delivery. This simple step of making 
members aware of the possibility of having to self-fund a 
confinement will make them consider their choice carefully. 
Funders would also have a role here by establishing the mJI 
anticipated mode of delivery when authorising the 
confinement, and following up with the expectant mother 
and/ or her doctor when an elective CS is planned. 
A forthcoming initiative that will almost certainly stimulate 
medical schemes and funders to review their CS rates is the 
Risk Equalisation Fund (REF). This has been under discussion 
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since 1994 and is moving towards implementation as part of 
the broader reform of social health insurance. The REF will 
begin as a 'shadow' exercise in 2005 (medical schemes submit 
data but no money changes hands), and it seems likely that full 
implementation will be in 2007. The link between CS and the 
REF lies in the fact that in this country we have some medical 
schemes with older members in whom chronic diseases of 
lifestyle and degeneration are the dominant cost drivers, and 
others with younger members in whom chronic disease rates 
are low but maternal and child health issues prevail. The latter 
fact and a uniquely South African phenomenon of (anti-) 
selective membership by women during the childbearing years, 
led to a recommendation by the expert panel that dealt with 
the mechanics of the REF to also equalise for maternity rates. 17 
However, the quantum that schemes receive will be based on a 
composite amount that incorporates the cost of both vaginal 
and operative delivery, and in calculating that amount the CS 
rate will definitely not be set at current levels of 60%. The 
intention of the Risk Equalisation Technical Advisory Panel 
making recommendations on the REF is to use a 50% CS 
weighting in the first year, i.e. the 2005 'shadow year/ and to 
reduce this proportion subject to annual audit and input from 
stakeholders. The REF will therefore create an incentive for 
schemes to reduce their funding levels for CS to at least that 
incorporated in the REF formula, and ideally to strive for even 
lower rates so as to maximise the value of the REF payment 
and channel funds into reserves, enhance other benefits, or 
reduce contributions. Identification of the patient-driven, 
medically unnecessary cases and introduction of co-payments 
(i.e. the cost difference between a vaginal and CS delivery) in 
such cases would also add 'efficiency' to the REF, as would 
performance-based contracts with networks of doctors. 
Conclusions 
Overall we believe that important industry-related pieces of the 
puzzle are falling into place and that any additional 
intervention from other bodies such as the Health Professions 
Council or the Department of Health would not only be 
unnecessary but also inappropriate. The BHF model 
introduces exactly the kind of thinking required to 
acknowledge and respect choice of level of care, but at a cost to 
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the patient; the REF will promote medical schemes' awareness 
of the financial implications and consequences of unmanaged 
CS rates, and development of networks and provider-funder 
contracts will result in mutually acceptable targets for 
procedures such as CS. However, maximum gain from these 
initiatives will depend on active communication strategies so 
that those who are most affected, i.e. the women themselves, 
are fully informed and not only able to appreciate the 
difference between CSs that are medically necessary and those 
that are not, but also that in the case of the latter they will 
likely be the ones to select and partially pay for the procedure 
and the right to exercise their choice. 
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